- Home
- CRBU vs CIK Comparison
CRBU vs CIK Comparison
Compare CRBU & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBU | CIK |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.8M | 134.4M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CRBU | CIK |
|---|---|---|
| Price | $1.57 | $2.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 917.9K | 406.1K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.63 | N/A |
| Revenue Next Year | $10.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $2.42 |
| 52 Week High | $3.53 | $3.01 |
Technical Indicators
Market Signals| Indicator | CRBU | CIK |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 48.75 |
| Support Level | $1.52 | $2.42 |
| Resistance Level | $1.72 | $2.57 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 10.64 | 50.00 |
Price Performance
Historical ComparisonAbout CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.